NCT01921582 is a Phase 2 clinical trial of Methylphenidate in Binge-Eating Disorder, sponsored by Centre for Addiction and Mental Health.

Who is sponsoring NCT01921582?

NCT01921582 is sponsored by Centre for Addiction and Mental Health.

What drugs are being tested in NCT01921582?

Interventions in NCT01921582: Methylphenidate, Cognitive Behavioral Therapy.

What condition does NCT01921582 study?

NCT01921582 studies Binge-Eating Disorder.

Is NCT01921582 still recruiting?

NCT01921582 is currently completed. Last updated 3 February 2017.

Last reviewed 2017-02-03 · How we verify

NCT01921582

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Comparison of Osmotic Release Oral System Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Obese Patients With Binge Eating Disorder

Completed Phase 2 Last updated 3 February 2017

What this trial tests

Phase 2 trial testing Methylphenidate in Binge-Eating Disorder in 51 participants. Completed in 1 September 2015.

Timeline

1 August 2013

Primary endpoint
1 September 2015

1 September 2015

Quick facts

Lead sponsor	Centre for Addiction and Mental Health
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	51
Start date	1 August 2013
Primary completion	1 September 2015
Estimated completion	1 September 2015
Sites	1 location across Canada

Drugs / interventions tested

Methylphenidate (methylphenidate) — full drug profile →
Cognitive Behavioral Therapy

Conditions studied

Binge-Eating Disorder — all drugs for Binge-Eating Disorder →

Sponsor

Centre for Addiction and Mental Health — full company profile →

Who can join

Adults 18 to 50, female only, with Binge-Eating Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Frequency of binge episodes/days, as assessed by prospective daily binge diary
Time frame: After 12 weeks of treatment

Sponsor's own description

The purpose of this study is to determine whether methylphenidate is effective in the treatment of binge eating disorder, in a randomized controlled trial extended release methylphenidate versus cognitive behavioral therapy for binge eating disorder in overweight or obese adult females.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current and emerging drug treatments for binge eating disorder.
Reas DL, Grilo CM. · · 2014 · cited 34× · PMID 24460483 · DOI 10.1517/14728214.2014.879291
Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof).
Hirsch D, Reed J, Naqvi A, Ngor A, et al · · 2026 · PMID 41313392 · DOI 10.1007/s40263-025-01248-7

Verify or expand the search:

Other trials of Methylphenidate

Trials testing the same drug.

NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
NCT06580041 — Precision Care for Major Depressive Disorder · Phase 4 · enrolling by invitation
NCT06355414 — Psilocybin in Chronic Low Back Pain and Depression · Phase 1 · recruiting
NCT05776056 — Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints · Phase 4 · recruiting

Other recruiting trials for Binge-Eating Disorder

Currently open trials in the same condition.

NCT07060534 — Building Healthy Eating and Self-Esteem Together for University Students · NA · recruiting
NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
NCT06819813 — Project VIBE: Virtual Intervention for Binge Eating in Adolescents · NA · recruiting
NCT06485687 — Low Intensity Focused Ultrasound for Binge Eating Disorder · NA · active not recruiting

Other Centre for Addiction and Mental Health trials

Trials by the same sponsor.

NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01921582 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
Last refreshed: 3 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01921582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing